Sana Biotechnology Highlights Publication in Nature Biotechnology of Novel In Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Tran...
Sana Biotechnology, Inc. (SANA)
Company Research
Source: Acquire Media Monitor
Additional proof-of-concept for the advancement of SC379, Sana's pluripotent stem cell-derived glial progenitor cell product candidate SEATTLE, May 21, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today highlighted that Nature Biotechnology has published a paper titled “ Young glial progenitor cells competitively replace aged and diseased human glia in the adult chimeric mouse brain .” This paper showed that when healthy wild-type (WT), pluripotent stem cell-derived glial progenitor cells (hGPCs) – the cells that give rise to the glial support cells of the brain – were transplanted into adult mice that had been neonatally transplanted with mutant Huntingtin (mHTT)-expressing hGPCs, the healthy cells outcompeted and eliminated the diseased glia, ultimately repopulating the brain with the healthy transplanted cells. These data establish an additional proof-of-concept for the develop
Show less
Read more
Impact Snapshot
Event Time:
SANA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SANA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SANA alerts
High impacting Sana Biotechnology, Inc. news events
Weekly update
A roundup of the hottest topics
SANA
News
- Sana Biotechnology to Present at September 2024 Investor ConferencesGlobeNewswire
- Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific OfficerGlobeNewswire
- Sana Biotechnology, Inc. (NASDAQ: SANA) had its price target raised by analysts at Citigroup Inc. from $8.00 to $15.00. They now have a "buy" rating on the stock.MarketBeat
- Sana Biotechnology, Inc. (NASDAQ: SANA) had its price target lowered by analysts at HC Wainwright from $12.00 to $11.00. They now have a "buy" rating on the stock.MarketBeat
- Sana Biotechnology Reports Second Quarter 2024 Financial Results and Business UpdatesGlobeNewswire
SANA
Earnings
- 8/8/24 - Miss
SANA
Sec Filings
- 8/8/24 - Form 10-Q
- 8/8/24 - Form 8-K
- 7/15/24 - Form 4/A
- SANA's page on the SEC website